Penumbra 3D Trial Results to be Presented at Late Breaking Abstract Presentations Session
ALAMEDA, Calif. – July 19, 2016 – Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced its schedule of key events at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting to be held July 25-28 in Boston, Massachusetts. These events include the presentation of the results of the randomized controlled clinical trial for the company’s next generation stent retriever, the Penumbra 3D Revascularization Device.
Key Events
Late Breaking Abstract Session
The results of the randomized controlled clinical trial for the Penumbra 3D Revascularization Device will be presented during the Late Breaking Abstract Presentations session on Wednesday, July 27 by Donald Frei, MD, of Radiology Imaging Associates/Swedish Medical Center. The Late Breaking Abstract Presentations session is scheduled for 11:35 a.m. ET – 12:20 p.m. ET.
The Penumbra 3D Trial is a prospective, randomized controlled non-inferiority study that compared the safety and efficacy of the Penumbra 3D Revascularization Device used in conjunction with Penumbra System aspiration devices with that of Penumbra System aspiration devices alone. The Penumbra 3D Revascularization Device is approved for investigational use only in the United States.
Industry Technology Luncheon Symposia
The company will feature its latest products at presentations to be held Monday, July 25 at 1:30-1:45 p.m. ET, Wednesday July 27 at 12:50-1:05 p.m. ET, and Thursday July 28 at 1:00-1:15 p.m. ET.
Stroke Awareness Event at Fenway Park
Penumbra will sponsor a public awareness event organized by The Joe Niekro Foundation together with The Bee Foundation on Tuesday, July 26, during the Boston Red Sox vs. Detroit Tigers baseball game at Fenway Park. The event will pay tribute to those lost to stroke and honor survivors, with the aim to increase visibility and awareness of stroke and its impact on patients and their families.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.
ALAMEDA, Calif. – July 19, 2016 – Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced its schedule of key events at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting to be held July 25-28 in Boston, Massachusetts. These events include the presentation of the results of the randomized controlled clinical trial for the company’s next generation stent retriever, the Penumbra 3D Revascularization Device.
Key Events
Late Breaking Abstract Session
The results of the randomized controlled clinical trial for the Penumbra 3D Revascularization Device will be presented during the Late Breaking Abstract Presentations session on Wednesday, July 27 by Donald Frei, MD, of Radiology Imaging Associates/Swedish Medical Center. The Late Breaking Abstract Presentations session is scheduled for 11:35 a.m. ET – 12:20 p.m. ET.
The Penumbra 3D Trial is a prospective, randomized controlled non-inferiority study that compared the safety and efficacy of the Penumbra 3D Revascularization Device used in conjunction with Penumbra System aspiration devices with that of Penumbra System aspiration devices alone. The Penumbra 3D Revascularization Device is approved for investigational use only in the United States.
Industry Technology Luncheon Symposia
The company will feature its latest products at presentations to be held Monday, July 25 at 1:30-1:45 p.m. ET, Wednesday July 27 at 12:50-1:05 p.m. ET, and Thursday July 28 at 1:00-1:15 p.m. ET.
Stroke Awareness Event at Fenway Park
Penumbra will sponsor a public awareness event organized by The Joe Niekro Foundation together with The Bee Foundation on Tuesday, July 26, during the Boston Red Sox vs. Detroit Tigers baseball game at Fenway Park. The event will pay tribute to those lost to stroke and honor survivors, with the aim to increase visibility and awareness of stroke and its impact on patients and their families.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.
